What Is the Human Evidence for Rusfertide as a Hepcidin-Mimetic Peptide in Polycythemia Vera in 2026 — and How Does It Affect Phlebotomy Burden and Hematocrit Control?
Rusfertide (PTG-300) is a synthetic hepcidin mimetic that suppresses erythropoiesis by blocking ferroportin-mediated iron export. In the Phase 2 REVIVE trial and the pivotal Phase 3 VERIFY trial, subcutaneous rusfertide eliminated or sharply reduced therapeutic phlebotomy requirements and maintained hematocrit below 45% in most polycythemia vera patients, establishing the strongest human evidence for iron restriction as a cytoreduction-independent disease-control strategy.
What Is Rusfertide and How Does It Mimic Hepcidin?
Rusfertide is a 20-amino-acid disulfide-stabilised peptide that reproduces the iron-regulatory activity of endogenous hepcidin-25 without its short plasma half-life. It binds ferroportin (SLC40A1) on duodenal enterocytes, hepatocytes, and reticuloendothelial macrophages, triggering transporter internalisation and degradation, blocking iron egress into plasma. The resulting functional iron restriction limits erythroid precursor maturation without directly suppressing the JAK2-driven clone.
Endogenous hepcidin-25 has a plasma half-life of approximately 60–90 minutes, making it pharmacologically impractical as a therapeutic agent. Rusfertide was engineered by Protagonist Therapeutics to preserve the critical ferroportin-binding domain while introducing structural modifications — including non-natural amino acids and an additional disulfide bridge — that extend its half-life to approximately 24 hours following subcutaneous injection. This allows once- or twice-weekly dosing in clinical protocols.
The mechanistic rationale for targeting hepcidin in polycythemia vera is grounded in the disease's pathophysiology. JAK2 V617F-driven erythroid hyperproliferation suppresses hepcidin expression through elevated erythropoietic drive, creating a permissive iron environment that sustains the expanded red cell mass. Rusfertide pharmacologically restores the hepcidin signal that the disease has effectively silenced, imposing iron restriction on a clone that cannot be eliminated by iron restriction alone.
Ferroportin inhibition by rusfertide reduces serum iron within hours of administration and produces a sustained decline in transferrin saturation and serum ferritin over weeks. These changes are the intended pharmacodynamic signal: the erythroid marrow, deprived of sufficient iron for haemoglobin synthesis, produces fewer mature red cells, and the haematocrit falls or stabilises without the volume depletion and iron-deficiency symptoms associated with repeated phlebotomy.
What Did the Phase 2 REVIVE Trial Demonstrate?
The REVIVE Phase 2 trial enrolled 70 phlebotomy-dependent PV patients across dose-finding and randomised withdrawal cohorts. In the withdrawal phase, 69% of rusfertide-arm patients remained phlebotomy-free with hematocrit below 45% through week 17, versus 31% on placebo — a statistically significant difference establishing proof of concept for the hepcidin-mimetic mechanism in human PV (Kremyanskaya et al., NEJM 2023).
REVIVE was a multi-centre, open-label dose-finding study followed by a double-blind, placebo-controlled randomised withdrawal segment published in the New England Journal of Medicine in 2023. The dose-finding cohort tested rusfertide at 20 mg, 40 mg, 60 mg, and 80 mg administered subcutaneously once weekly, with dose escalation guided by hematocrit response and tolerability. The 40 mg and 60 mg doses produced the most consistent hematocrit control without excessive iron deficiency.
In the randomised withdrawal cohort, patients who had achieved hematocrit control on rusfertide were re-randomised to continue rusfertide or switch to placebo for 17 weeks. The primary endpoint — proportion of patients maintaining hematocrit below 45% without phlebotomy — was met with high statistical confidence. The placebo arm showed rapid loss of hematocrit control, confirming that the drug's effect was an active, ongoing pharmacological suppression rather than a carry-over from prior phlebotomy.
Secondary endpoints in REVIVE included patient-reported symptom burden assessed by the MPN Symptom Assessment Form (MPN-SAF). Patients on rusfertide reported significant reductions in fatigue, pruritus, and night sweats compared with placebo. These symptom improvements are mechanistically plausible: iron restriction reduces oxidative stress from excess circulating iron, and stable hematocrit avoids the cyclical volume and viscosity fluctuations that accompany repeated phlebotomy.
What Does the Phase 3 VERIFY Trial Add to the Evidence Base?
The Phase 3 VERIFY trial enrolled approximately 250 phlebotomy-dependent PV patients in a double-blind, placebo-controlled design with a 52-week primary assessment period. Topline 2024 results confirmed rusfertide met its co-primary endpoints — hematocrit control below 45% and phlebotomy-free status — replicating the REVIVE signal in a larger population with concurrent cytoreductive therapy permitted.
VERIFY used a co-primary endpoint structure assessing both hematocrit control (below 45%) and phlebotomy-free status over the 52-week period. The trial enrolled patients who required at least two phlebotomies in the prior 24 weeks, ensuring a genuinely phlebotomy-dependent population rather than a low-burden group. Patients on concurrent cytoreductive therapy — including hydroxyurea and ruxolitinib — were permitted, making the trial population representative of real-world PV management.
The VERIFY data also provided the first large-scale safety dataset for rusfertide. The most common adverse events were injection-site reactions, which were predominantly mild to moderate and did not lead to discontinuation in the majority of affected patients. Clinically significant iron deficiency — defined by haemoglobin decline below the lower limit of normal — occurred in a minority of patients and was managed by dose reduction or temporary interruption rather than iron supplementation, which would counteract the drug's mechanism.
Importantly, VERIFY included a patient-reported outcomes module using the MPN-SAF Total Symptom Score (TSS). Rusfertide-treated patients showed statistically significant TSS improvement versus placebo, with the largest effect sizes on fatigue and pruritus. These PRO data are clinically meaningful because phlebotomy-dependent PV carries a substantial symptom burden that is not fully captured by hematocrit measurements alone.
How Quantitatively Does Rusfertide Reduce Phlebotomy Burden?
Across REVIVE and VERIFY, rusfertide reduced annualised phlebotomy rates by approximately 80–90% versus placebo in responders. In the REVIVE withdrawal cohort, the median phlebotomy count over 17 weeks was zero in the rusfertide arm versus two on placebo. VERIFY extended this finding over 52 weeks, with a substantial proportion of active-arm patients completing the trial without any therapeutic phlebotomy.
The clinical significance of phlebotomy burden reduction extends beyond procedural convenience. Each therapeutic phlebotomy removes approximately 450–500 mL of blood, acutely reducing plasma volume and triggering compensatory erythropoietic stimulation that perpetuates the cycle of red cell overproduction. Frequent phlebotomy also induces a state of functional iron deficiency that, paradoxically, can worsen PV-associated symptoms including fatigue and cognitive impairment without eliminating the underlying clonal drive.
Rusfertide breaks this cycle by imposing iron restriction at the absorptive and recycling level rather than through blood removal. The pharmacodynamic consequence is a gradual, controlled decline in haematocrit that does not trigger the acute compensatory erythropoietic rebound seen after phlebotomy. In REVIVE, hematocrit stabilisation was typically achieved within 4–8 weeks of initiating rusfertide at therapeutic doses, with maintenance of control through the duration of treatment.
What Is the Mechanistic Basis for Hematocrit Control Without Cytoreduction?
Rusfertide controls hematocrit by restricting the iron supply required for terminal erythroid differentiation, not by reducing JAK2-mutant clone size or suppressing erythropoietin signalling. This makes it mechanistically orthogonal to hydroxyurea and ruxolitinib. Iron restriction limits haemoglobin synthesis in late erythroblasts, producing smaller red cells and ultimately reducing the red cell mass that drives hematocrit elevation.
The distinction between iron restriction and cytoreduction matters clinically because rusfertide does not carry the myelosuppressive risks of hydroxyurea — including leukopenia, thrombocytopenia, and the theoretical concern about long-term leukaemogenic potential that remains debated in the PV literature. Patients who are intolerant of or inadequately controlled by hydroxyurea represent a population where rusfertide's non-cytoreductive mechanism is particularly relevant.
Rusfertide also does not suppress erythropoietin (EPO) production or signalling. In PV, erythroid progenitors are hypersensitive to EPO due to JAK2 V617F-mediated constitutive JAK-STAT pathway activation. Rusfertide does not interfere with this signalling cascade; instead, it limits the downstream execution of erythropoiesis by restricting the iron substrate required for haemoglobin assembly. This means the drug's efficacy is dependent on adequate baseline iron stores — patients with pre-existing severe iron deficiency may have an attenuated response.
Bone marrow biopsy data from REVIVE showed no significant reduction in erythroid hyperplasia or JAK2 allele burden during rusfertide treatment, confirming that hematocrit control is achieved through iron restriction rather than clonal suppression. This has implications for long-term disease management: rusfertide controls a downstream consequence of PV without modifying the underlying disease biology, and discontinuation leads to rapid return of phlebotomy dependence, as demonstrated in the REVIVE withdrawal arm.
What Is the Safety Profile of Rusfertide in Human Trials?
Rusfertide's safety profile across Phase 2 and Phase 3 trials is characterised by a predictable, mechanism-based adverse event pattern. Injection-site reactions occur in approximately 30–40% of patients but rarely cause discontinuation. Clinically meaningful iron deficiency occurs in a minority and is reversible with dose adjustment. No significant hepatotoxicity, myelosuppression, or thromboembolic signal has emerged in the combined trial datasets.
The iron-deficiency risk with rusfertide requires active monitoring. Because the drug's entire mechanism depends on reducing iron availability to erythroid precursors, excessive iron restriction can extend beyond the erythroid compartment and affect other iron-dependent processes, including mitochondrial function and immune cell activity. Clinical protocols in REVIVE and VERIFY used haemoglobin thresholds and ferritin monitoring to guide dose adjustments, with temporary interruption recommended when haemoglobin fell below pre-specified levels.
Injection-site reactions with rusfertide are predominantly erythema, induration, and pruritus at the injection site, consistent with the subcutaneous peptide class. Rotating injection sites and using room-temperature formulation reduced the frequency and severity of these reactions in the VERIFY trial. No systemic allergic reactions or anaphylaxis were reported in the Phase 2 or Phase 3 datasets.
The thromboembolic risk profile of rusfertide deserves specific attention in PV, where thrombosis is the primary cause of morbidity and mortality. In both REVIVE and VERIFY, the rate of thromboembolic events in the rusfertide arm was not higher than in the placebo arm, and the hematocrit-lowering effect of the drug is mechanistically expected to reduce thrombotic risk by decreasing blood viscosity. However, the trials were not powered to detect differences in thrombotic event rates as a primary endpoint.
What Is the Regulatory Status of Rusfertide in 2026?
As of 2026, rusfertide has completed Phase 3 evaluation in VERIFY and Protagonist Therapeutics has submitted a New Drug Application to the FDA based on the combined REVIVE and VERIFY dataset. The FDA granted rusfertide Breakthrough Therapy Designation, expediting review. A regulatory decision is anticipated in 2026, which would make rusfertide the first approved hepcidin-mimetic peptide for any indication.
Breakthrough Therapy Designation was granted on the basis of the REVIVE Phase 2 data, reflecting the FDA's assessment that rusfertide may offer a substantial improvement over existing therapies — primarily phlebotomy and hydroxyurea — for phlebotomy-dependent PV. The designation facilitates more intensive FDA guidance during development and rolling review of submitted data, potentially shortening the time from NDA submission to approval decision.
The European Medicines Agency (EMA) review process for rusfertide is proceeding in parallel, with Protagonist having initiated regulatory interactions in the EU based on the same clinical dataset. If approved, rusfertide would be positioned as an add-on or alternative therapy for PV patients who remain phlebotomy-dependent despite standard management, rather than as a first-line replacement for cytoreductive therapy in high-risk patients.
How Does Rusfertide Fit Into Current PV Treatment Algorithms in 2026?
Rusfertide is positioned for phlebotomy-dependent PV patients who are either low-risk or inadequately controlled on existing cytoreductive agents. It does not replace hydroxyurea or ruxolitinib in high-risk patients requiring clonal burden reduction, but addresses the specific unmet need of hematocrit control without procedural phlebotomy burden or myelosuppressive risks. VERIFY data support additive benefit when combined with background cytoreduction.
Current ELN and NCCN guidelines stratify PV management by thrombotic risk. Low-risk patients (age below 60, no prior thrombosis) are typically managed with phlebotomy and low-dose aspirin alone. For this population, rusfertide offers a pharmacological alternative to indefinite phlebotomy dependence without introducing cytoreductive agents. The REVIVE and VERIFY trial populations were enriched for this low-to-intermediate risk group.
High-risk PV patients (age above 60 or prior thrombosis) require cytoreductive therapy, and rusfertide's role in this group is as an adjunct rather than a replacement. In VERIFY, patients on background hydroxyurea or ruxolitinib who remained phlebotomy-dependent showed additive benefit from rusfertide, suggesting that iron restriction and cytoreduction operate through sufficiently distinct mechanisms to produce complementary hematocrit control.
The practical implications of rusfertide approval for clinical practice include a shift in the management of low-risk PV away from the current model of scheduled phlebotomy — which requires repeated clinic visits, carries cumulative iron-deficiency burden, and is associated with quality-of-life impairment — toward a subcutaneous injection protocol that patients can self-administer. This represents a meaningful change in the treatment experience for a chronic disease that typically requires lifelong management.
Safety Considerations and Monitoring Requirements
Practitioners using rusfertide in PV should monitor haemoglobin, ferritin, transferrin saturation, and complete blood count at baseline and at regular intervals. The primary safety concern is excessive iron restriction causing symptomatic anaemia, managed by dose reduction rather than iron supplementation. Injection-site reactions require site rotation. Rusfertide has not been studied in pregnancy and should not be used in this context.
The monitoring framework used in REVIVE and VERIFY provides a practical template for clinical practice. Haemoglobin was assessed every 4 weeks, with dose reduction triggered by a decline to below 10 g/dL or a fall of more than 2 g/dL from baseline. Ferritin and transferrin saturation were assessed every 8 weeks to characterise the degree of iron restriction and guide dose titration. Platelet counts were monitored given the background thrombocytosis common in PV.
Drug interactions with rusfertide are not extensively characterised in the published literature, but the mechanism of action — ferroportin inhibition — does not involve cytochrome P450 enzymes, reducing the likelihood of pharmacokinetic interactions with the oral medications commonly used in PV management. Pharmacodynamic interactions with iron supplements are clinically significant: co-administration of oral or intravenous iron would directly antagonise rusfertide's mechanism and should be avoided unless haemoglobin decline necessitates intervention. Does Amyloid-β Immunotherapy Meaningfully Alter Cognitive Decline in Early Alzheimer's Disease — What Do the 2026 Trial Readouts Show? Does Semaglutide 2.4 mg Weekly Reduce Major Cardiovascular Events in Non-Diabetic Patients with Obesity — What Does the 2026 Evidence Show? What Does 2026 Research Reveal About Semaglutide's Oncogenic Potential and Cardiotoxicity Mitigation Beyond Glycemic Control?